Zkusit zdarma
Structure Therapeutics Inc.

Structure Therapeutics Inc.

GPCR
Cena:
$ 39.19
+0.40 (1.03%)
Valuace
70
Růst
23
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million

10:19 24-05-2026

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on meta...

Monashee Scales Back Its Bet on Structure Therapeutics

Monashee Scales Back Its Bet on Structure Therapeutics

15:27 20-05-2026

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targ...

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

14:22 17-05-2026

This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centere...

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

2:35 11-05-2026

Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co.,...

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

16:05 07-05-2026

Reported positive results from aleniglipron Phase 2 ACCESS II study  with up to 16.3% body weight l...

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

16:05 27-04-2026

SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clin...

Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR

Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR

4:43 06-04-2026

Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics Inc. Sponsored AD...

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages

4:08 04-04-2026

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) have been given...

What's Going On With Structure Therapeutics Stock On Wednesday?

What's Going On With Structure Therapeutics Stock On Wednesday?

14:07 01-04-2026

• What's the outlook for GCPR shares?...

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

16:06 22-03-2026

B Group acquired 90,000 shares of Structure Therapeutics in the fourth quarter. The quarter-end posi...

Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript

Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript

12:32 16-03-2026

Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Stu...

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

10:46 16-03-2026

Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight i...

Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%

Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%

9:27 16-03-2026

The stock's rise comes as the company reported significant weight loss results from its investigatio...

Why Weight-Loss Contender Structure Therapeutics Just Shot Skyward

Why Weight-Loss Contender Structure Therapeutics Just Shot Skyward

9:13 16-03-2026

Structure Therapeutics shares surged Monday after the biotech said its daily pill helped patients lo...

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages

4:32 10-03-2026

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) have been given...

Aberdeen Group plc Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Aberdeen Group plc Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

4:21 19-02-2026

Aberdeen Group plc increased its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR...

Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?

Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?

16:51 18-02-2026

Structure Therapeutics Inc. has evolved from a “dark horse” to a leading contender in the oral G...

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake

15:22 17-02-2026

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to...

Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company

Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company

3:38 12-02-2026

Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Co...

Principal Financial Group Inc. Decreases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Principal Financial Group Inc. Decreases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

4:30 08-02-2026

Principal Financial Group Inc. lowered its holdings in shares of Structure Therapeutics Inc. Sponsor...

close

NXERA PHARMA LICENSES GPCR-TARGETED PROGRAM TO NEWLY FOUNDED SPIN-OUT COMPANY

12-02-2026
TOKYO, JAPAN AND CAMBRIDGE, UK, 12 JANUARY 2026 – NXERA PHARMA CO., LTD. (“NXERA” OR “THE CO...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES CLOSING OF UPSIZED $747.5 MILLION PUBLIC OFFERING OF ADSS AND PRE-FUNDED WARRANTS AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS

11-12-2025
SAN FRANCISCO, DEC. 11, 2025 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $650 MILLION PUBLIC OFFERING OF ADSS AND PRE-FUNDED WARRANTS

09-12-2025
SAN FRANCISCO, DEC. 09, 2025 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES PROPOSED $500 MILLION PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND PRE-FUNDED WARRANTS

08-12-2025
SAN FRANCISCO, DEC. 08, 2025 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM ACCESS PROGRAM FOR ITS ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST, ALENIGLIPRON

08-12-2025
PLACEBO-ADJUSTED MEAN WEIGHT LOSS OF 11.3% (27.3 LBS) WITH 120 MG DOSE IN THE 36-WEEK PHASE 2B ACCES...
Více zde

STRUCTURE THERAPEUTICS TO REPORT DATA FROM ACCESS CLINICAL PROGRAM OF ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST, ALENIGLIPRON, ON DECEMBER 8, 2025

07-12-2025
SAN FRANCISCO, DEC. 07, 2025 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

06-11-2025
TOPLINE 36-WEEK DATA FROM ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST ALENIGLIPRON ACCESS AND ACCESS ...
Více zde

STRUCTURE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

06-08-2025
TOPLINE DATA FROM ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST ALENIGLIPRON ACCESS AND ACCESS II STUDI...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES TWO LATE-BREAKING POSTER PRESENTATIONS AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS INCLUDING NEW PRECLINICAL DATA FOR ORAL SMALL MOLECULE AMYLIN AGONIST, ACCG-2671

20-06-2025
SAN FRANCISCO, JUNE 20, 2025 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS TO PARTICIPATE IN MULTIPLE UPCOMING HEALTHCARE INVESTOR CONFERENCES

30-01-2025
SAN FRANCISCO, JAN. 30, 2025 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES SELECTION OF LEAD ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 FOR THE TREATMENT OF OBESITY

17-12-2024
PRECLINICAL STUDIES WITH ACCG-2671 DEMONSTRATE POTENT TARGET ENGAGEMENT, ROBUST WEIGHT LOSS, FAVORAB...
Více zde

STRUCTURE THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES LONDON HEALTHCARE CONFERENCE

15-11-2024
SAN FRANCISCO, NOV. 15, 2024 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2B ACCESS CLINICAL STUDY EVALUATING ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST, GSBR-1290, FOR OBESITY

13-11-2024
PHASE 2B ACCESS STUDY DESIGNED TO EVALUATE MULTIPLE DOSES UP TO 120 MG OF GSBR-1290  OVER 36 WEEKS ...
Více zde

NXERA PHARMA AND ANTIVERSE ENTER COLLABORATION TO DESIGN NOVEL GPCR-TARGETED ANTIBODY THERAPEUTICS USING GENERATIVE AI

05-11-2024
TOKYO, JAPAN AND LONDON AND CARDIFF, UK, 5 NOVEMBER 2024 – NXERA PHARMA (“NXERA”; TSE 4565) ...
Více zde

STRUCTURE THERAPEUTICS STRENGTHENS EXECUTIVE TEAM WITH PROMOTION OF BLAI COLL, M.D., PH.D. TO CHIEF MEDICAL OFFICER AND APPOINTMENT OF ASHLEY HALL, J.D.

17-09-2024
SAN FRANCISCO, SEPT. 17, 2024 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLIN...
Více zde

STRUCTURE THERAPEUTICS APPOINTS ANGUS C. RUSSELL TO BOARD OF DIRECTORS

27-08-2024
FORMER SHIRE CEO BRINGS MORE THAN 30 YEARS OF EXPERIENCE IN BUILDING AND SCALING COMPANIES IN THE GL...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

26-08-2024
SAN FRANCISCO, AUG. 26, 2024 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL AMERICAN DEPOSITARY SHARES

07-06-2024
SAN FRANCISCO, JUNE 07, 2024 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $476 MILLION PUBLIC OFFERING

05-06-2024
SAN FRANCISCO, JUNE 05, 2024 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND PRE-FUNDED WARRANTS

03-06-2024
SAN FRANCISCO, JUNE 03, 2024 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM ITS PHASE 2A OBESITY STUDY AND CAPSULE TO TABLET PK STUDY FOR ITS ORAL NON-PEPTIDE SMALL MOLECULE GLP-1 RECEPTOR AGONIST GSBR-1290

03-06-2024
GSBR-1290 ACHIEVED A CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT PLACEBO-ADJUSTED MEAN WEIGH...
Více zde

STRUCTURE THERAPEUTICS TO PRESENT AT LEERINK PARTNERS GLOBAL BIOPHARMA CONFERENCE

08-03-2024
SAN FRANCISCO, MARCH 08, 2024 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLIN...
Více zde

STRUCTURE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

08-03-2024
TOPLINE GSBR-1290 PHASE 2A 12-WEEK OBESITY DATA, AS WELL AS DATA FROM FORMULATION BRIDGING AND TITRA...
Více zde

STRUCTURE THERAPEUTICS PROVIDES COMPREHENSIVE GSBR-1290 PROGRAM UPDATE INCLUDING CLINICALLY MEANINGFUL PROOF-OF-CONCEPT DATA FROM PHASE 2A CLINICAL STUDY

18-12-2023
GSBR-1290 WAS GENERALLY WELL-TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS OVER 12 WEEK...
Více zde

STRUCTURE THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

14-11-2023
ANNOUNCED POSITIVE RESULTS FROM PHASE 1B CLINICAL STUDY OF ORAL GLP-1 RECEPTOR AGONIST, GSBR-1290, D...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES $300 MILLION PRIVATE PLACEMENT EQUITY FINANCING

29-09-2023
$300 MILLION FINANCING INCLUDES SIGNIFICANT PARTICIPATION FROM A NUMBER OF LARGE HEALTHCARE DEDICATE...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 1B CLINICAL STUDY OF ORAL GLP-1 RECEPTOR AGONIST GSBR-1290 AND PROVIDES PROGRAM UPDATE

29-09-2023
GSBR-1290 SHOWN TO BE GENERALLY WELL-TOLERATED WITH NO ADVERSE EVENT-RELATED DISCONTINUATIONS IN PHA...
Více zde

STRUCTURE THERAPEUTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

10-08-2023
COMPLETED ENROLLMENT IN 12-WEEK PHASE 2A STUDY OF ORAL GLP-1 RECEPTOR AGONIST, GSBR-1290 TOPLINE DAT...
Více zde

STRUCTURE THERAPEUTICS APPOINTS TED W. LOVE, M.D.

03-08-2023
SAN FRANCISCO, AUG. 03, 2023 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINI...
Více zde

STRUCTURE THERAPEUTICS ANNOUNCES POSTER PRESENTATIONS OF ITS ORAL GLP-1 RECEPTOR AGONIST GSBR-1290 AT THE AMERICAN DIABETES ASSOCIATION 83RD SCIENTIFIC SESSIONS

07-06-2023
SAN FRANCISCO AND SHANGHAI, CHINA, JUNE 07, 2023 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NA...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-05 00:00:008-KStáhnout
2025-12-10 00:00:008-KStáhnout
2025-12-08 00:00:008-KStáhnout
2025-11-06 00:00:008-KStáhnout
2025-11-06 00:00:0010-QStáhnout
2025-08-06 01:00:008-KStáhnout
2025-08-06 01:00:0010-QStáhnout
2025-08-06 00:00:008-KStáhnout
2025-08-06 00:00:0010-QStáhnout
2025-06-25 01:00:008-KStáhnout
2025-06-25 00:00:008-KStáhnout
2025-05-08 01:00:008-KStáhnout
2025-05-08 01:00:0010-QStáhnout
2025-05-08 00:00:008-KStáhnout
2025-05-08 00:00:0010-QStáhnout
2025-02-27 00:00:008-KStáhnout
2025-02-27 00:00:0010-KStáhnout
2025-02-26 23:00:008-KStáhnout
2025-02-26 23:00:0010-KStáhnout
2024-12-17 00:00:008-KStáhnout
2024-12-16 23:00:008-KStáhnout
2024-11-13 00:00:008-KStáhnout
2024-11-13 00:00:0010-QStáhnout
2024-11-12 23:00:008-KStáhnout
2024-11-12 23:00:0010-QStáhnout
2024-09-17 01:00:008-KStáhnout
2024-09-17 00:00:008-KStáhnout
2024-08-27 01:00:008-KStáhnout
2024-08-27 00:00:008-KStáhnout
2024-08-08 01:00:008-KStáhnout
2024-08-08 01:00:0010-QStáhnout
2024-08-08 00:00:008-KStáhnout
2024-08-08 00:00:0010-QStáhnout
2024-06-27 01:00:008-KStáhnout
2024-06-27 00:00:008-KStáhnout
2024-06-03 01:00:008-KStáhnout
2024-06-03 00:00:008-KStáhnout
2024-05-09 01:00:008-KStáhnout
2024-05-09 01:00:0010-QStáhnout
2024-05-09 00:00:008-KStáhnout
2024-05-09 00:00:0010-QStáhnout
2024-03-08 00:00:008-KStáhnout
2024-03-08 00:00:0010-KStáhnout
2024-03-07 23:00:008-KStáhnout
2024-03-07 23:00:0010-KStáhnout
2023-12-18 00:00:008-KStáhnout
2023-12-17 23:00:008-KStáhnout
2023-11-17 00:00:0010-QStáhnout
2023-11-16 23:00:0010-QStáhnout
2023-11-14 00:00:008-KStáhnout
2023-11-13 23:00:008-KStáhnout
2023-09-29 01:00:008-KStáhnout
2023-09-29 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-08-04 01:00:008-KStáhnout
2023-08-04 00:00:008-KStáhnout
2023-07-06 01:00:008-KStáhnout
2023-07-06 00:00:008-KStáhnout
2023-06-05 01:00:008-KStáhnout
2023-06-05 00:00:008-KStáhnout
2023-05-11 01:00:008-KStáhnout
2023-05-11 01:00:0010-QStáhnout
2023-05-11 00:00:008-KStáhnout
2023-05-11 00:00:0010-QStáhnout
2023-03-30 01:00:008-KStáhnout
2023-03-30 01:00:0010-KStáhnout
2023-03-30 00:00:008-KStáhnout
2023-03-30 00:00:0010-KStáhnout
2023-02-07 00:00:008-KStáhnout
2023-02-06 23:00:008-KStáhnout
preloader